Sign in Subscribe

FDA Fast Tracks Promising Immunotherapy Greenwich's GLSI-100 for Breast Cancer Recurrence

FDA Fast-Tracks GLSI-100, an immunotherapy for HER2+ breast cancer. It aims to prevent recurrence in HLA-A*02 patients. Early data showed >80% reduction in recurrence & good safety. Now in Phase III, it could save lives by preventing metastatic spread.

FDA Fast Tracks Promising Immunotherapy Greenwich's GLSI-100 for Breast Cancer Recurrence
Photo by National Cancer Institute on Unsplash

This post is for paying subscribers only

Already have an account? Sign in.